Trial Profile
A randomised, open-label, two-way crossover, single- and multiple-dose relative bioavailability study of tofacitinib extended-release (XR) and tofacitinib immediate-release (IR)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Mar 2016
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Atopic dermatitis; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 21 Mar 2016 New trial record
- 11 Mar 2016 Results from this and other phase I study, published in the Journal of Clinical Pharmacology.